Free thyroid hormons ration in patients with amiodaron-induced thyrotoxicosis type 1 and type 2

Differentiation between amiodarone-induced thyrotoxicosis type 1 (AmIT1) and type 2 (AmIT2) is a diagnostic challenge. The current diagnostic tests are often unable to differentiate these two types of thyrotoxic syndrome. Several studies had shown that the serum T4 level and T3/T4 ratio are significantly different in patients with destructive thyroiditis, and those with Graves` disease. These studies showed that the serum T4 concentration is significantly higher, and the T3/T4 ratio is significantly lower in patients with destructive forms of thyroiditis compared to their values  in Graves’ disease. Since AmIT1 is known to develop in patients with latent Graves` disease, and AmIT2 is a destructive thyroiditis, the purpose of our study was to evaluate the serum FТ4 level and FT4/FT3 ratio in AmIT1 and AmIT2 as an additional diagnostic test for differentiating these types of thyrotoxicosis. 45 patients with thyrotoxicosis (33 with AmIT1 and 12 AmIT2) were included in the study. The diagnosis of thyrotoxicosis type (AmIT1 or AmIT2) was established on the basis of clinical data, color flow Doppler sonography (CFDS), the presence of TSH receptor autoantibody in patients with AmIT1, as well as the effect of treatment. There was no difference in FT3 levels in patients with AmIT1 and AmIT2, while the FT4 values were significantly higher in patients with AmIT2 (36,2±19,1 mmol/L) than in those with AmIT1 (17,8±3,7 mmol/L, p= 0,002). Also, a difference in the FT4/FT3 ratio was found between AmIT1 (2,7±0,8) and AmIT2 (6,1±5,7, p=0,048). Moreover, 75% of patients with AmIT1 had FT4/FT3ratio < 3,10, while 75% of patients with AmIT2 had FT4/FT3 ratio > 3,65. The FT4/FT3 ratio can be used as an additional test in the differential diagnosis AmIT1 and AmIT2.

amiodarone-induced thyrotoxicosis, FТ3, FТ4, FТ4/FТ3 ratio

1. Martino E, Bartalena L, Bogazzi F, Braverman LE. The Effects of Amiodarone on the Thyroid. Endocrine Reviews. 2001; 22: 240 — 254.

2. Bogazzi F, Bartalena L, Gasperi M. et al. The Various Effects of Amiodarone on Thyroid Function Thyroid. 2001; 11: 511-519.

3. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function Nat. Rev. Endocrinol.2009; 6:34–41.

4. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Practice Research Clinical Endocrinology Metabolism. 2009; 23:735–751.

5. Grineva EN, Dora SV, Malakhova TV, Malakhova ZL. Influence of amiodarone on the thyroid gland structure and function. Problems of Endocrinology. 2008; 54: 17-21 (in Russian)

6. Grineva EN, Babenko AYu, Vygovskiyi AB. Amiodaron-induced thyrotoxicosis: Difficulties in diagnosis and care. Problems of Endocrinology. 2005; 51(4): 18 (in Russian)

7. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118: 706-714.

8. Bogazzi F, Bartalena L, Martino E. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. JCEM. 2010; 95: 2529–2535.

9. Pattison DA, Westcott J, Lichtenstein M, et al: Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nuclear Medicine Communications. 2015; 36: 356–362.

10. Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009; 25: 421-424.

11. Bogazzi F, Martino E, Dell’Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis J. Endocrinol. Invest. 2003; 26: 635-640.

12. Eaton SEM, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography Clinical Endocrinology. 2002; 56: 33–38.

13. Barvalia U, Amlani B, Pathak R. Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge. Hindawi Publishing Corporation Case Reports in Medicine Volume. 2014; Article ID 231651, 1-6.

14. Tanda ML, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008; 69:812 — 818.

15. Sriphrapradang C, Bhasipol A. Differentiating Graves’ disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. Annals of Medicine and Surgery. 2016; 10: 69-72.

16. Yoshimura Noh J, Momotani N, Fukada S, et al. Ratio of serum free triiodothyronine to free thyroxine in Graves’ hyperthyroidism and thyrotoxicosis caused by painless thyroiditis, Endocr. J. 2005; 52: 537-542.

17. Yanagisawa T, Sato K, Kato Y. et al. Rapid differential diagnosis of Graves’ disease and painless thyroiditis using total T3/T4 ratio, TSH, and total alkaline phosphatase activity. Endocr J. 2005; 52:29-36.

18. Bogazzi F, Bartalena L, Brogioni S. et al. Color flow Doppler sonography rapidly differentiates typeI and type II amiodarone-induced thyrotoxicosis. Thyroid. 1997; 7: 541545.

19. Bogazzi F, Bartalena L, Dell’Unto E. et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clinical Endocrinology. 2007; 67: 533–537.

20. Carle ́ A, Knudsen N, Bu ̈low Pedersen I, et al. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. Eur JEndocrinol. 2013; 169: 537–545.

21. Martino E, Safran M, Aghini-Lombardi F. et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984; 101:28 — 34.

22. Sidhu, J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK. QJM. 2003; 96: 949–950.

23. Amino N, Yabu Y, Miki T. et al. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves’ disease and destruction-induced thyrotoxicosis. JCEM. 1981; 53: 113–116.

24. Laurberg P. Mechanisms Governing the Relative Proportions of Thyroxine and 3,5,3’-Triiodothyronine in Thyroid Secretion Metabolism. 1984; 33: 379-392.

25. Laurberg P, Vestergaard H, Nielsen S. et al. Sources of Circulating 3,5,3`-Triiodothyronine in Hyperthyroidism Estimated after Blocking of Type 1 and Type 2 Iodothyronine Deiodinases. JCEM. 2007; 92: 2149 –2156.

26. Salvatore D, Tu H, Harney JW, Larsen R. Type 2 Iodothyronine Deiodinase Is Highly Expressed in Human Thyroid J. Clin. Invest. 1996; 98:962–968.

27. Murakami M, Araki O, Hosoi Y. et al. Expression and Regulation of Type II Iodothyronine Deiodinase in Human Thyroid Gland. Endocrinol. 2001; 142: 2961- 2967.

28. Nelson JC, Wang R, Asher DT, Wilcox RB. Underestimates and overestimates of total thyroxine concentrations caused by unwanted thyroxine-binding protein effects. Thyroid. 2005; 15: 12–15.

29. Shigemasa C, Abe K, Taniguchi S. et al. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves’ disease despite similar serum total T4 levels. JCEM. 1987; 65: 359–363.

30. Izumi Y, Hidaka Y, Tada H. et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. Clin Endocrinol (Oxf). 2002; 57: 51–58.